Medicare expenditures for Stelara have increased almost tenfold, from $300 million in 2016 to almost $3 billion in 2023. Medicare paid 80% more, on average, for the same drug used to treat the same ...
Alvotech and Teva Pharmaceuticals have received approval from the Food and Drug Administration for Selarsdi (ustekinumab-aekn) injection as a biosimilar to Janssen's Stelara. Designed for subcutaneous ...
Everyday Health on MSN
7 Common Crohn's Disease Medication Side Effects and How to Cope With Them
Several Crohns medications can cause skin problems like acne, rashes, and thinning skin. [For example,] anti-TNF alpha agents ...
Please provide your email address to receive an email when new articles are posted on . Pyzchiva, an ustekinumab biosimilar, is approved for all indications of the reference medicine, including ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued a permanent, product-specific billing code for Otulfi (ustekinumab-aauz). Under ...
Funding a head-to-head study against a rival is risky. When that rival’s initials are “J” and “J,” it’s an even riskier bet. However, it’s just the sort of endeavor that appears to have paid off for ...
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the ...
This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback